Altered tryptophan metabolism in Parkinson's disease: A possible novel therapeutic approach

  title={Altered tryptophan metabolism in Parkinson's disease: A possible novel therapeutic approach},
  author={Nikoletta Szab{\'o} and Zsigmond Tam{\'a}s Kincses and J{\'o}zsef Toldi and L{\'a}szl{\'o} V{\'e}csei},
  journal={Journal of the Neurological Sciences},

Figures and Tables from this paper

The kynurenine pathway in neurodegenerative diseases: Mechanistic and therapeutic considerations
Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington’s Disease
A summary of the current understanding of the role of IDO1 in Huntington’s disease is provided and this enzyme is assessed as a potential therapeutic target for HD.
The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases
Emerging evidence suggests that neuroinflammation is involved in both depression and neurodegenerative diseases. The kynurenine pathway, generating metabolites which may play a role in pathogenesis,
Pharmacological validation of TDO as a target for Parkinson’s disease
The data support TDO inhibition as a potential therapeutic strategy to decrease motor, cognitive, and gastrointestinal symptoms in Parkinson’s disease.
Riboflavin Has Neuroprotective Potential: Focus on Parkinson’s Disease and Migraine
The role of riboflavin in neuroprotection is emphasized elaborating on its proposed neuroprotective mechanisms in opposite to the pathogenesis-related mechanisms involved in two common neurological disorders, PD and migraine headache, as well as encouraging the clinical evaluation of rib oflavinIn this article, it is found that ribOflavin ameliorates oxidative stress, mitochondrial dysfunction, neuroinflammation, and glutamate excitotoxicity.
Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs
The review discusses the pharmacokinetic properties of levodopa (LD) and factors influencing them, the pharmacodynamics of LD and approaches with the aim of improving this, covering some of the other antiparkinson medications available.
Safinamide for the treatment of Parkinson's disease
The authors believe that safinamide is a valuable drug in the treatment of PD treatment with favorable pharmacokinetic and side-effect profiles and suggest that it can be used beneficially as add-on therapy both to DAAs in early PD and to LD in the later stages of the disease.
Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid
Two natural molecules, kynurenic acid and α-lipoic acid are potential candidates for neuroprotective therapies suitable in managing neurodegenerative diseases and the dietary supplement pantethine is a universal antioxidant.


Kynurenine metabolism in multiple sclerosis
The involvement of the kynurenine system in the pathogenesis of MS, which may predict a novel therapeutic intervention, is demonstrated.
The role of kynurenines in disorders of the central nervous system: Possibilities for neuroprotection
Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies
The experimental data indicate that neuroprotection can be achieved by both alternatives, suggesting opportunities for further drug development in this field.
Tryptophan metabolism and oxidative stress in patients with Huntington's disease
It is concluded that patients with HD exhibit abnormal handling of tryptophan metabolism and increased oxidative stress, and that these factors could contribute to ongoing brain dysfunction.
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex
Kynurenine metabolism in Alzheimer's disease
The present data indicate an elevated kynurenine metabolism in AD brain and a marked increase of KYNA in the caudate nucleus and putamen may compensate the hyperactivity of the striato-frontal loop in AD brains.
Kynurenine pathway abnormalities in Parkinson's disease
3-O-methyldopa (3OMD) concentration appears to be a reliable marker of L-dopa therapy, and may be a further indication of a defect in NADH:ubiquinone oxidoreductase (complex I) in mitochondria in Parkinson's disease (PD).